Literature DB >> 27034797

Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma.

Aniruddha Jakharia1, Biswajyoti Borkakoty1, Sujay Singh1.   

Abstract

BACKGROUND: SPARC-like protein 1 (SPARCL1/Hevin), a member of the SPARC family is defined by the presence of a highly acidic domain-I, a follistatin-like domain, and an extracellular calcium (EC) binding domain. SPARCL1 has been shown to be down-regulated in many types of cancer and may serve as a negative regulator of cell growth and proliferation.
METHODS: Both tumor and adjacent normal tissue were collected from patients with gastric adenocarcinoma. Monoclonal antibody developed against recombinant SPARCL1 was used to analyze the expression of SPARCL1 by immunohisto chemical and western blotting (WB) analysis.
RESULTS: The expression of SPARCL1 was found to be significantly lower or negligible in gastric adenocarcinoma tissues in nearly all of the cases in comparison with adjacent normal tissue. This comparison was found to be independent of the patient's age, sex, and stage of cancer.
CONCLUSIONS: We postulate that down regulation of SPARCL1 may be related to inactivation of its tumor suppressor functions and might play an important role in the development of gastric adenocarcinoma.

Entities:  

Keywords:  SPARC-like protein 1 (SPARCL1); gastric adenocarcinoma; hevin; hybridoma

Year:  2016        PMID: 27034797      PMCID: PMC4783736          DOI: 10.3978/j.issn.2078-6891.2015.064

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  19 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.

Authors:  Ping Li; Jianxin Qian; Guanzhen Yu; Ying Chen; Ke Liu; Jie Li; Jiejun Wang
Journal:  J Surg Oncol       Date:  2011-08-30       Impact factor: 3.454

3.  Expression of SC1 is associated with the migration of myotomes along the dermomyotome during somitogenesis in early mouse embryos.

Authors:  M Ringuette; I Rogers; S Varmuza; S Rush; I R Brown
Journal:  Dev Genes Evol       Date:  1998-09       Impact factor: 0.900

Review 4.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer.

Authors:  I Bendik; P Schraml; C U Ludwig
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

6.  Errors in the technique of intraperitoneal injection of mice.

Authors:  J P Steward; E P Ornellas; K D Beernink; W H Northway
Journal:  Appl Microbiol       Date:  1968-09

7.  Intraperitoneal injection of mice.

Authors:  N A Miner; J Koehler; L Greenaway
Journal:  Appl Microbiol       Date:  1969-02

8.  Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.

Authors:  Irene Esposito; Hany Kayed; Shereen Keleg; Thomas Giese; E Helene Sage; Peter Schirmacher; Helmut Friess; Jörg Kleeff
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

9.  Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.

Authors:  Fang Cao; Kuo Wang; Rong Zhu; Yong-Wei Hu; Wen-Zheng Fang; Hou-Zhong Ding
Journal:  Asian Pac J Cancer Prev       Date:  2013

10.  Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation.

Authors:  A Claeskens; N Ongenae; J M Neefs; P Cheyns; P Kaijen; M Cools; E Kutoh
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  5 in total

1.  SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.

Authors:  Yan Ma; Yuan Xu; Li Li
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

2.  Associations of tumor suppressor SPARCL1 with cancer progression and prognosis.

Authors:  Ting Li; Xia Liu; Antai Yang; Wenjie Fu; Fuqiang Yin; Xiaoyun Zeng
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

3.  Prognostic value of SPARCL1 in patients with colorectal cancer.

Authors:  Wei Han; Fang Cao; Wei Ding; Xiao-Jiao Gao; Fang Chen; Yong-Wei Hu; Hou-Zhong Ding
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

4.  5-Year Survival in Gastric Adenocarcinoma with Epithelial and Stromal Versican Expression.

Authors:  Mohammad Hossein Sanei; Omid Mirmosayyeb; Ali Chehrei; Jamshid Ansari; Elahe Saberi
Journal:  Iran J Pathol       Date:  2018-12-27

5.  Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.

Authors:  Anika Klingler; Daniela Regensburger; Clara Tenkerian; Nathalie Britzen-Laurent; Arndt Hartmann; Michael Stürzl; Elisabeth Naschberger
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.